Remodulin

March 28, 2019April 18, 2019

Sandoz Launches Treprostinil Injection, First Remodulin Generic, in the US for PAH Treatment

News, PAH News

The pharmaceutical company Sandoz announced the commercialization of an injectable form of the vasodilating therapy treprostinil for treating exercise-related symptoms affecting individuals with pulmonary arterial hypertension (PAH). This treprostinil ... Read more

February 11, 2019February 11, 2019

Wireless Monitoring May Help Transition of Therapy in PAH, Study Suggests

News

An implantable wireless system may help guide the transition from medication administered intravenously — Remodulin (treprostinil) — to one taken orally — Uptravi (selexipag) — in the treatment of pulmonary arterial hypertension (PAH), according ... Read more

January 2, 2019January 15, 2019

FDA Approves Medtronic’s Implantable System for Remodulin for Treatment of PAH

News, PAH News

The U.S. Food and Drug Administration has approved Medtronic’s Implantable System for Remodulin, or ISR, to deliver Remodulin to patients with pulmonary arterial hypertension (PAH). PAH patients have high blood ... Read more

April 4, 2018December 21, 2018

The Bucket List I Refuse to Make

Columns, Life After PH – A Column By Kathleen Sheffer

During my senior year of high school, a teacher assigned the task of creating a “bucket list.” I was furious. A term popularized by the 2007 movie of the ... Read more

February 23, 2018February 23, 2018

Remodulin Safe, Effective in Treating CTD-PAH for 12 Months, Observational Study Shows

News, PAH News

Subcutaneous Remodulin (treprostinil), marketed by United Therapeutics, is to be safe and effective for at least 12 months in patients with congenital heart disease-related pulmonary arterial hypertension (CTD-PAH), an observational study ... Read more

January 16, 2018January 16, 2018

Heart Blood Pressure Tool Unable to Predict Survival of PAH Patients on Remodulin, Study Finds

News, PAH News

A tool for estimating blood pressure on the left side of the heart is unable to predict the long-term survival of pulmonary hypertension patients taking Remodulin, a study reports. The ... Read more

January 12, 2018January 12, 2018

United Therapeutics and Corsair to Work Together on Skin Patch to Deliver Pulmonary Hypertension Therapy

News, PAH News

United Therapeutics and Corsair Pharma are teaming up to advance Corsair’s development of a blood-vessel-widening skin patch for treating pulmonary arterial hypertension. The patch will contain treprostinil, which is already ... Read more

January 5, 2018January 5, 2018

Sixty Pulmonary Hypertension Patients Receive Implanted-pump Therapy-delivery Systems

News, PAH News

Researchers implanted a long-term, intravenous therapy-delivery system consisting of internal pumps and catheters in 60 pulmonary arterial hypertension (PAH) patients, according to a clinical trial. The IV infusion system, developed ... Read more

Remodulin

Sandoz Launches Treprostinil Injection, First Remodulin Generic, in the US for PAH Treatment

Wireless Monitoring May Help Transition of Therapy in PAH, Study Suggests

Top 10 Pulmonary Hypertension Stories of 2018

FDA Approves Medtronic’s Implantable System for Remodulin for Treatment of PAH

The Bucket List I Refuse to Make

Remodulin Safe, Effective in Treating CTD-PAH for 12 Months, Observational Study Shows

Heart Blood Pressure Tool Unable to Predict Survival of PAH Patients on Remodulin, Study Finds

United Therapeutics and Corsair to Work Together on Skin Patch to Deliver Pulmonary Hypertension Therapy

Top 10 Pulmonary Hypertension Articles of 2017

Sixty Pulmonary Hypertension Patients Receive Implanted-pump Therapy-delivery Systems

Pin It on Pinterest